Anthem Biosciences Limited (ANTHEM) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 16, 2026 3 min read

Anthem Biosciences enters Q1 FY27 with a strong tailwind as the global destocking cycle concludes and the company leverages its fully integrated CRDMO platform. Investors will be focused on the margin trajectory following a record-setting Q4 and the progress of critical growth levers, including the GLP-1 commercialization timeline and the massive Unit IV greenfield expansion.

Quick Details

Results date	July 21, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 6,109 Mn
Previous quarter PAT	Rs. 1,898 Mn
Previous quarter EBITDA margin	48.1%
Net debt (latest quarter)	Net Cash of Rs. 13,743 Mn
Market cap	Rs. 42,284.69 Cr
CMP	Rs. 750.8

Anthem Biosciences Limited Q1 Results Date and Time

The board meeting is scheduled for July 21, 2026, to consider the unaudited standalone and consolidated financial results for Q1 FY27.

What to expect from Anthem Biosciences Limited's Q1 FY27 results

Anthem Biosciences is expected to show robust YoY revenue growth in Q1 FY27, supported by the resolution of customer destocking and a weaker INR, which averaged approximately Rs. 95.3–95.5 per USD during the quarter. While sequential revenue is likely to moderate from the record Rs. 6,109 Mn reported in Q4 FY26, EBITDA margins should remain well above the 38.0% base seen in Q1 FY26 due to structural backward integration and operating leverage. Management is expected to provide a crucial update on the commercialization timeline for GLP-1 products, which was previously targeted within 6-8 months of May 2026. The company's capital allocation remains a focal point, with investors monitoring the deployment of the planned Rs. 700 Cr capex for FY27 to support the Unit IV greenfield expansion. Finally, the path to profitability for the Neoanthem Unit III facility will be scrutinized as the company aims for a long-term asset turnover of 1.4x-1.5x.

Key Things To Watch

GLP-1 commercialization progress: Tracking the 6-8 month timeline provided in May 2026 for material contribution.

Status of customer and regulatory approvals for the integrated fermentation and synthesis platform
Updated outlook on revenue contribution potential given the cost advantage over Chinese competitors

Unit IV greenfield expansion: Monitoring the execution of the Phase 1 investment exceeding Rs. 1,200 Cr.

Progress on the 30-acre Harohalli site construction toward the March 2028 commissioning target
Alignment of Q1 capex spend with the Rs. 700 Cr guidance for FY27

Unit III (Neoanthem) ramp-up: Evaluating the transition of the facility toward profitability.

Revenue run-rate and path to achieving 1.4x-1.5x asset turnover
Commissioning status of the fermentation block and its impact on capacity utilization

Operating metric trajectory: Assessing the sustainability of margin drivers.

Impact of restocking on Q1 revenue trajectory compared to the 59.6% YoY growth in Q1 FY26
Employee cost management as a percentage of sales amidst calibrated headcount additions for new units

Frequently Asked Questions

What was the impact of the destocking cycle on Anthem Biosciences?

Management confirmed in Q4 FY26 that the destocking cycle is resolved and customers are now restocking. This shift is expected to positively impact top and bottom-line performance in the current year.

How does the company maintain its margin profile?

Margins are supported by structural backward integration, which allows the company to manufacture intermediates in-house rather than relying on external supplies. This strategy has consistently kept gross margins above 65%.

What is the status of the Unit IV expansion project?

Unit IV is a 30-acre greenfield site in Harohalli, Bengaluru, with a Phase 1 investment of over Rs. 1,200 Cr. The project is targeted for commissioning by March 2028.